Piramal Pharma Limited — Board Meeting, 05-11-2025: Outcome of Board Meeting

Piramal Pharma's board approved consolidated Q2/H1 FY26 financial results. Q2 saw a net loss of Rs 99.22 Cr on Rs 2,043.72 Cr revenue. H1 net loss was Rs 180.92 Cr with Rs 3,977.44 Cr revenue. An exceptional gain of Rs 20.74 Cr from a supplier claim was also reported.